secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2025-11-24T23:59:59+00:00
Accession:  0001628280-25-053816
Event type: debt
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna enters $1.5B credit facility with Ares; $600M initial term loan, $900M delayed draw
--------------------------------------------------------------------------------

- $1.5B facility: $600M initial term loan and $900M delayed draw tranche available through Nov 2027/2028.
- Interest at Term SOFR + 5.50% or base rate + 4.50%; maturity date November 24, 2030.
- Secured by all assets of Moderna; guaranteed by US, Canadian, UK, Swiss, and Australian subsidiaries.
- Minimum liquidity covenant of $500M ($750M if >$1B drawn); not tested if market cap >$5B.
- Proceeds used for general corporate purposes; loan contingent on regulatory milestones for delayed draw portion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000162828025053816/0001628280-25-053816-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000162828025053816/mrna-20251119.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-053816

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer